AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21208151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl orally disintegrating tablet (ODT)
Number of subjects: 139
Study 21208151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl ODT
Number of subjects: 139
Study 21208408 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 171
Study 21208408 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 171
Study 21208408 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP at 24 h
Number of subjects: 171
Study 21208408 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP at 48 h
Number of subjects: 171
Study 21208408 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP at discharge
Number of subjects: 171
Study 21208408 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP pre-discharge
Number of subjects: 171
Study 21208408 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP and NT-proBNP
Number of subjects: 171
Study 21208579 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 395
Study 21209029 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH deficiency
Number of subjects: 248
Study 21209029 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendocrine studies
Number of subjects: 248
Study 21209029 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants
Number of subjects: 248
Study 21209029 — intervention group
Group type: EXPERIMENTAL
Intervention: KAL1 variants
Number of subjects: 248
Study 21209881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment
Number of subjects: 0
Study 21209881 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study 21209881 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0
Study 21209881 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo pioglitazone treatment
Number of subjects: 0
Study 21210835 — intervention group
Group type: EXPERIMENTAL
Intervention: RVED area in males
Number of subjects: 2088
Study 21210835 — intervention group
Group type: EXPERIMENTAL
Intervention: RVED area for men
Number of subjects: 2088
Study 21210835 — intervention group
Group type: EXPERIMENTAL
Intervention: RVED area for women
Number of subjects: 2088
Study 21210835 — intervention group
Group type: EXPERIMENTAL
Intervention: RVED area indexed to BSA for men
Number of subjects: 2088
Study 21210835 — intervention group
Group type: EXPERIMENTAL
Intervention: RVED area indexed to BSA for women
Number of subjects: 2088
Study 21210835 — intervention group
Group type: EXPERIMENTAL
Intervention: RVED area
Number of subjects: 2088
Study 21210835 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung capacity measured as FVC
Number of subjects: 2088
Study 21211990 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (anti-CD20) therapy
Number of subjects: 25
Study 21212386 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variant rs1436109 (NCAM1)
Number of subjects: 3563
Study 21212386 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis across all stages
Number of subjects: 3563
Study 21212770 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal BMI threshold of 30 kg/m2 in white women
Number of subjects: 6436
Study 21212770 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal BMI threshold of 32.9 kg/m2 in AA women
Number of subjects: 6436
Study 21212770 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal BMI threshold of 29.1 kg/m2 in white men
Number of subjects: 6436
Study 21212770 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal BMI threshold of 30.4 kg/m2 in AA men
Number of subjects: 6436
Study 21212770 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal WC threshold of 91.9 cm in white women
Number of subjects: 6436
Study 21212770 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal WC threshold of 96.8 cm in AA women
Number of subjects: 6436
Study 21212770 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal WC threshold of 99.4 cm in white men
Number of subjects: 6436
Study 21212770 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal WC threshold of 99.1 cm in AA men
Number of subjects: 6436
Study 21213475 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-day regimen of drospirenone and ethinyl estradiol
Number of subjects: 52218
Study 21213475 — intervention group
Group type: COMPARATOR
Intervention: 21-day regimens of other progestogens
Number of subjects: 52218
Study 21213475 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-day regimen of drospirenone
Number of subjects: 52218
Study 21213475 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 52218
Study 21216311 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-HIV (high dose 10^9 pfu/2 ml)
Number of subjects: 150
Study 21216311 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV-HIV (heterologous boost)
Number of subjects: 150
Study 21216311 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous boosting regimen
Number of subjects: 150
Study 21216311 — intervention group
Group type: COMPARATOR
Intervention: Heterologous vector boost
Number of subjects: 150
Study 21216475 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI Citalopram
Number of subjects: 0
Study 21216475 — intervention group
Group type: EXPERIMENTAL
Intervention: Various medications administered in level 3
Number of subjects: 0
Study 21216880 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PARC/CCL-18 levels in COPD patients
Number of subjects: 0
Study 21216880 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated PARC/CCL-18 levels
Number of subjects: 0
Study 21217080 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitted cell counts (PIT)
Number of subjects: 193
Study 21217080 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Howell-Jolly bodies (HJB)
Number of subjects: 193
Study 21217080 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver-spleen scan
Number of subjects: 193
Study 21217520 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)-based immunotherapy
Number of subjects: 60
Study 21219411 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous sildenafil bolus
Number of subjects: 0
Study 21219411 — intervention group
Group type: COMPARATOR
Intervention: 20 mg oral sildenafil tablet
Number of subjects: 0
Study 21219434 — intervention group
Group type: EXPERIMENTAL
Intervention: Always used injection-meal interval (Type 1 diabetes); n=39, age 58 years, duration of diabetes 21.1 years, BMI 28.7 kg/m², HbA(1c) 7.50%/58 mmol/mol
Number of subjects: 433
Study 21219434 — intervention group
Group type: EXPERIMENTAL
Intervention: Always used injection-meal interval (Type 2 diabetes); n=124, age 65 years, duration of diabetes 13.8 years, BMI 32.6 kg/m², HbA(1c) 7.31%/56 mmol/mol
Number of subjects: 433
Study 21220472 — intervention group
Group type: EXPERIMENTAL
Intervention: CBP501 alone (0.9 mg/m(2), D1/D8/D15, q4w)
Number of subjects: 0
Study 21220472 — intervention group
Group type: EXPERIMENTAL
Intervention: CBP501 in combination with cisplatin (3.6 mg/m(2) CBP501, 50 mg/m(2) cisplatin, both on D1, q3w)
Number of subjects: 0
Study 21220472 — intervention group
Group type: EXPERIMENTAL
Intervention: CBP501/cisplatin combination
Number of subjects: 0
Study 21220675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (ChEIs) and memantine hydrochloride
Number of subjects: 590
Study 21220675 — intervention group
Group type: COMPARATOR
Intervention: Cholinesterase inhibitors (ChEIs) only
Number of subjects: 590
Study 21220996 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels in patients with acute lung injury/acute respiratory distress syndrome (n=15)
Number of subjects: 64
Study 21220996 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels in patients with acute lung injury/acute respiratory distress syndrome plus severe sepsis/septic shock (n=18)
Number of subjects: 64
Study 21220996 — intervention group
Group type: COMPARATOR
Intervention: sRAGE levels in patients with severe sepsis/septic shock (n=16)
Number of subjects: 64
Study 21220996 — intervention group
Group type: COMPARATOR
Intervention: sRAGE levels in mechanically ventilated controls (n=15)
Number of subjects: 64
Study 21220996 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of sRAGE levels with acute lung injury/acute respiratory distress syndrome severity
Number of subjects: 64
Study 21220996 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels over time
Number of subjects: 64
Study 21220996 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline plasma sRAGE
Number of subjects: 64
Study 21222188 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium assessment using the Confusion Assessment Method on postoperative days two, four, and discharge.
Number of subjects: 88
Study 21222188 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychometric testing at discharge and three months following surgery.
Number of subjects: 88
Study 21222188 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis to evaluate predictors of delirium and POCD.
Number of subjects: 88
Study 21222188 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E-ε4 genotype assessment.
Number of subjects: 88
Study 21224253 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary weight management program
Number of subjects: 67
Study 21224368 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-322 (BMS-844203) 2 mg/kg i.v. weekly (qw) or biweekly (q2w)
Number of subjects: 39
Study 21224368 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-322 (BMS-844203) 0.1 to 3.0 mg/kg i.v. qw or q2w
Number of subjects: 39
Study 21224368 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-322 (BMS-844203) 3.0 mg/kg i.v. qw or q2w
Number of subjects: 39
Study 21224368 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-322 (BMS-844203)
Number of subjects: 39
Study 21225123 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratus-OCT
Number of subjects: 40
Study 21225123 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard automated perimetry (SAP)
Number of subjects: 40
Study 21225123 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy eyes)
Number of subjects: 40
Study 21226540 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 index < 4.0 (high risk) in obese children (BMI z-score > 2.25)
Number of subjects: 0
Study 21226540 — intervention group
Group type: COMPARATOR
Intervention: Higher omega-3 index (6.0-8.0 lower risk) in non-obese children
Number of subjects: 0
Study 21226540 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between omega-3 index and fasting insulin level
Number of subjects: 0
Study 21226540 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between omega-3 index and HOMA scores
Number of subjects: 0
Study 21226927 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg loading dose, followed by 75 mg daily)
Number of subjects: 504
Study 21226927 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg loading dose, followed by 100 mg daily)
Number of subjects: 504
Study 21226927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine or prasugrel (if available and not contraindicated)
Number of subjects: 504
Study 21226927 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured therapy plan based on a 'test and treat' strategy
Number of subjects: 504
Study 21227674 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 4635
Study 21227674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4635
Study 21227674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 4635
Study 21227674 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 4635
Study 21227674 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 4635
Study 21228328 — intervention group
Group type: COMPARATOR
Intervention: melphalan-prednisone alone (n = 332)
Number of subjects: 1175
Study 21228328 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan-prednisone-thalidomide (n = 332)
Number of subjects: 1175
Study 21228328 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan-prednisone-bortezomib (n = 257)
Number of subjects: 1175
Study 21228328 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan-prednisone-bortezomib-thalidomide (n = 254)
Number of subjects: 1175
Study 21229597 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Interview for Cognitive Status (TICS) screening
Number of subjects: 343
Study 21229597 — intervention group
Group type: EXPERIMENTAL
Intervention: TICS scores
Number of subjects: 343
Study 21229597 — intervention group
Group type: EXPERIMENTAL
Intervention: TICS
Number of subjects: 343
Study 21232152 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine dependence (FTND score)
Number of subjects: 842
Study 21232152 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower FTND score, male gender, lower body mass index, and lower FEV1
Number of subjects: 842
Study 21232152 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants in CHRNA3/5
Number of subjects: 842
Study 21232152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine dependence
Number of subjects: 842
Study 21232715 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1302
Study 21232716 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus-eluting stent (EES)
Number of subjects: 4692
Study 21232717 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 2738
Study 21232717 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 2738
Study 21232745 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-1 G insertion
Number of subjects: 204
Study 21232745 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-9≥22 repeats
Number of subjects: 204
Study 21232745 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent angina and NSTEMI
Number of subjects: 204
Study 21233271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren (PTC124) lower dose (4, 4 and 8 mg·kg(-1))
Number of subjects: 19
Study 21233271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren (PTC124) higher dose (10, 10 and 20 mg·kg(-1))
Number of subjects: 19
Study 21233705 — intervention group
Group type: EXPERIMENTAL
Intervention: DIEP flap perfusion measured by laser Doppler imager
Number of subjects: 14
Study 21234288 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast health supplement containing HMR lignan, indole-3-carbinol, calcium glucarate, milk thistle, Schisandra chinesis and stinging nettle for 28 days
Number of subjects: 96
Study 21234288 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 96
Study 21236414 — intervention group
Group type: EXPERIMENTAL
Intervention: Under-corrected spectacles up to -1.5 D
Number of subjects: 38
Study 21236414 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal tolerable amount of under-correction (mean -0.89 D)
Number of subjects: 38
Study 21239695 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 90 mg/m² days 1 and 4; Rituximab 375 mg/m² day 1; Bortezomib 1.3 mg/m² days 1, 4, 8, 11 (6 cycles of 28 days)
Number of subjects: 30
Study 21239695 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine, Bortezomib, and Rituximab combination
Number of subjects: 30
Study 21239698 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavopiridol (30-mg/m(2) bolus, 60-mg/m(2) infusion)
Number of subjects: 55
Study 21239698 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavopiridol (30-mg/m(2) bolus, 70-mg/m(2) infusion)
Number of subjects: 55
Study 21241171 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban underserved group
Number of subjects: 1514
Study 21241171 — intervention group
Group type: COMPARATOR
Intervention: Rural underserved group
Number of subjects: 1514
Study 21242187 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-induction therapy
Number of subjects: 94
Study 21242187 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of FLT3-internal tandem duplication
Number of subjects: 94
Study 21242187 — intervention group
Group type: EXPERIMENTAL
Intervention: Age above the median of 47 years
Number of subjects: 94
Study 21242187 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the negative prognostic factors (FLT3-internal tandem duplication, age above median)
Number of subjects: 94
Study 21242187 — intervention group
Group type: EXPERIMENTAL
Intervention: One negative prognostic factor (FLT3-internal tandem duplication or age above median)
Number of subjects: 94
Study 21242187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both negative prognostic factors (FLT3-internal tandem duplication and age above median)
Number of subjects: 94
Study 21242187 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation after relapse
Number of subjects: 94
Study 21242491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandutinib 500 mg twice daily
Number of subjects: 6
Study 21242992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (open-label treatment for 8 weeks)
Number of subjects: 38
Study 21242992 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 individuals)
Number of subjects: 38
Study 21244307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole prolonged release (PR), maximum 24 mg/day
Number of subjects: 83
Study 21244307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole prolonged release (PR)
Number of subjects: 83
Study 21245420 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab with chemotherapy
Number of subjects: 799
Study 21245726 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP measured at baseline
Number of subjects: 515
Study 21245726 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP (highest vs lowest quartile)
Number of subjects: 515
Study 21245726 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP (after adjustment for covariates)
Number of subjects: 515
Study 21245726 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP (after additional adjustment for IL-6, high-sensitivity C-reactive protein, and D-dimer)
Number of subjects: 515
Study 21245868 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with therapeutic anticoagulation (TA)
Number of subjects: 3
Study 21245868 — intervention group
Group type: COMPARATOR
Intervention: Placebo with therapeutic anticoagulation (TA)
Number of subjects: 3
Study 21247312 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in genes associated with idiopathic hypogonadotropic hypogonadism in women with hypothalamic amenorrhea (FGFR1, PROKR2, GNRHR, KAL1)
Number of subjects: 55
Study 21247312 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies of identified mutations
Number of subjects: 55
Study 21247312 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal menstrual cycles
Number of subjects: 55
Study 21247313 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesions
Number of subjects: 697
Study 21247313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit lesions
Number of subjects: 697
Study 21247313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with plaque burden of 70% or greater
Number of subjects: 697
Study 21247313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with minimal luminal area of 4.0 mm² or less
Number of subjects: 697
Study 21247313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit lesions classified as thin-cap fibroatheromas
Number of subjects: 697
Study 21247313 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall major adverse cardiovascular events
Number of subjects: 697
Study 21248153 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection drug users (IDUs)
Number of subjects: 87
Study 21248153 — intervention group
Group type: COMPARATOR
Intervention: Nonaddicts
Number of subjects: 87
Study 21248153 — intervention group
Group type: EXPERIMENTAL
Intervention: SAB
Number of subjects: 87
Study 21249218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite infusion (starting dose at 4.2 µg/kg/hr; maximal dose of 533.8 µg/kg/hr)
Number of subjects: 12
Study 21249218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite infusion
Number of subjects: 12
Study 21249218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite infusion at maximal tolerated dose
Number of subjects: 12
Study 21251599 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training intervention
Number of subjects: 22
Study 21251599 — intervention group
Group type: COMPARATOR
Intervention: Health training control
Number of subjects: 22
Study 21251631 — intervention group
Group type: EXPERIMENTAL
Intervention: SXscore tertile SX(HIGH) >16
Number of subjects: 807
Study 21251631 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination SYNTAX-PAMI score
Number of subjects: 807
Study 21251631 — intervention group
Group type: EXPERIMENTAL
Intervention: SXscore
Number of subjects: 807
Study 21251631 — intervention group
Group type: EXPERIMENTAL
Intervention: PAMI score
Number of subjects: 807
Study 21251631 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SYNTAX-PAMI score
Number of subjects: 807
Study 21251673 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alfuzosin XL for 12 months
Number of subjects: 108
Study 21252039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive abilities assessed using Free and Cued Selective Recall Reminding Test (FCSRT)
Number of subjects: 686
Study 21252039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive abilities assessed using Benton visual retention test
Number of subjects: 686
Study 21252039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive abilities assessed using similarities subtest of the Wechsler Adult Intelligence Scale-Revised
Number of subjects: 686
Study 21252039 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and cognitive complaints measured at baseline
Number of subjects: 686
Study 21252240 — intervention group
Group type: EXPERIMENTAL
Intervention: Incretin effect measured over 6 days with three 4-h oral glucose tolerance tests (25, 75, and 125 g)
Number of subjects: 8
Study 21252240 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance tests with increasing glucose loads
Number of subjects: 8